Welcome to our dedicated page for Avricore Health SEC filings (Ticker: AVCRF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Avricore Health Inc. filings document the company's foreign private issuer reporting and disclosures for the HealthTab pharmacy testing platform. Its Form 6-K reports furnish annual and interim financial statements, management discussion and analysis, officer certifications, and news releases covering HealthTab platform activity.
The filing record also reflects Avricore Health's use of Form 20-F status, Canadian issuer certifications, and material updates related to community pharmacy testing initiatives, including UK expansion materials and health-system pilot disclosures.
Avricore Health Inc. (AVCRF) furnishes a Form 6-K for August 2026 that primarily transmits several Canadian disclosure documents and news releases to U.S. investors. Exhibits include a news release on HealthTab™ entering a multi-year collaboration agreement with Abbott for point-of-care testing across the UK, a material change report, a news release on Avricore granting options, and interim financial statements and MD&A, each dated in late August 2026.
The filing also includes a Canadian Form 52-109FV2 Venture Issuer Basic Certificate, in which Chief Financial Officer Kiki Smith certifies Avricore’s interim filings as of August 31, 2026. The certificate notes that, as a venture issuer, the representations do not cover establishing and maintaining disclosure controls and procedures or internal control over financial reporting under National Instrument 52-109, and that this may result in additional risks to the quality, reliability, transparency and timeliness of the company’s filings.
Avricore Health Inc., a foreign private issuer based in Vancouver, submitted a report listing multiple disclosures for the period around March 31, 2026. The company furnished an interim financial statements report for March 31, 2026 and a related interim MD&A for March 31, 2026, together with CEO and CFO certifications of those interim filings dated June 1, 2026.
The report also includes a news release titled “Avricore Health Closes $1.254 Million Financing” dated June 17, 2026, and a Canadian Form 45-106F1 Report of Exempt Distribution dated June 23, 2026. Extensive instructions are provided on how issuers or underwriters must file exempt distribution reports across Canadian jurisdictions, including use of specific security type codes and disclosure of confidential purchaser and control person information.
Avricore Health Inc. filed a Form 6-K as a foreign private issuer for January 2026. The filing primarily furnishes a news release titled “HealthTab to Expand Across North East London,” indicating the company is highlighting expansion activity related to its HealthTab platform in that region.
Avricore Health Inc. submitted a Form 6-K as a foreign private issuer for November 2025. The filing mainly furnishes a news release titled “HealthTab to Power NHS Pilot”, listed as Exhibit 1 and dated November 27, 2025. The report is signed on behalf of the company by Chief Financial Officer Kiki Smith on December 10, 2025, confirming the news release as official company communication.